Maintaining tumor heterogeneity in patient-derived tumor xenografts

Cancer Research

Volumn 75, Issue 15, 2015, Pages 2963-2968

  Cassidy, John W ^a   Caldas, Carlos ^a   Bruna, Alejandra ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC RESEARCH; CANCER GROWTH; CELL HETEROGENEITY; EX VIVO STUDY; GENETIC HETEROGENEITY; GENOMICS; HUMAN; IN VIVO STUDY; NONHUMAN; PATIENT DERIVED TUMOR XENOGRAFT; PRIORITY JOURNAL; REVIEW; STROMA; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; TUMOR HETEROGENEITY; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ANIMAL; DISEASE MODEL; DRUG SCREENING; EXPERIMENTAL NEOPLASM; MOUSE; PATHOLOGY; XENOGRAFT;

ANIMALS; DISEASE MODELS, ANIMAL; HETEROGRAFTS; HUMANS; MICE; NEOPLASMS, EXPERIMENTAL; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942866389     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-0727     Document Type: Review

References (33)

1. Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and trans criptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012;486:346-52.
2. Huang M, Shen A, Ding J, Geng M. Molecularly targeted cancer therapy: some lessons from the past decade. Trends Pharmacol Sci 2014;35: 41-50.
3. Shaw AT, Kim D-W, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.
4. Diaz LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012;486:537-40.
5. Eirew P, Steif A, Khattra J, Ha G, Yap D, Farahani H, et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 2014;518:422-6.
6. Nguyen LV, Cox CL, Eirew P, Knapp DJHF, Pellacani D, Kannan N, et al. DNA barcoding reveals diverse growth kinetics of human breast tumour subclones in serially passaged xenografts. Nat Commun 2014;5:5871.
7. Kreso A, O'Brien CA, van Galen P, Gan OI, Notta F, Brown AMK, et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 2013;339:543-8.
8. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013;19:1423-37.
9. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012;487:500-4.
10. Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 2014;4:998-1013.
11. Whittle JR, Lewis MT, Lindeman GJ, Visvader JE. Patient-derived xenograft models of breast cancer and their predictive power. Breast Cancer Res 2015;17. doi:10.1186/s13058-015-0523-1.
12. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011;146:633-44.
13. Cleary AS, Leonard TL, Gestl SA, Gunther EJ. Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature 2014;508:113-7.
14. Aparicio S, Caldas C. The implications of clonal genome evolution for cancer medicine. N Engl J Med 2013;368:842-51.
15. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012;486:395-9.
16. Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A, et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol 2013;231: 21-34.
17. Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 2006;38:468-73.
18. Fischer A, Vazquez-García I, Illingworth CJR, Mustonen V. High-definition reconstruction of clonal composition in cancer. Cell Rep 2014;7:1740-52.
19. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010;464:999-1005.
20. Murtaza M, Dawson S-J, Tsui DWY, Gale D, Forshew T, Piskorz AM, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013;497:108-12.
21. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 2012;12:323-34.
22. Kreso A, van Galen P, Pedley NM, Lima-Fernandes E, Frelin C, Davis T, et al. Self-renewal as a therapeutic target in human colorectal cancer. Nat Med 2014;20:29-36.
23. Michor F, Weaver VM. Understanding tissue context influences on intra-tumour heterogeneity. Nat Cell Biol 2014;16:301-2.
24. Wang C-C, Bajikar SS, Jamal L, Atkins KA, Janes KA. A time- and matrix-dependent TGFBR3-JUND-KRT5 regulatory circuit in single breast epithelial cells and basal-like premalignancies. Nat Cell Biol 2014;16:345-56.
25. Cassidy JW. Nanotechnology in the regeneration of complex tissues. Bone Tissue Regen Insights 2014;5:25-35.
26. Augsten M. Cancer-as sociated fibroblasts as another polarized cell type of the tumor microenvironment. Front Oncol 2014;4:62.
27. Argent R, Kumari R, Clarke P, Onion D, Lobo D, Grabowska A, et al. Restoration of paracrine signalling within the tumour microenvironment increases tumour growth and activation of c-Met [abstract]. In: Proceedings of the 10th NCRI Cancer Conference Poster Session C. Nottingham: NCRI; 2014. Abstract nr. LB186.
28. Yagi H, Kitagawa Y. The role of mesenchymal stem cells in cancer development. Front Genet 2013;4:261.
29. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014;515:577-81.
30. Schmidt M, Bohm D, Von Torne C, Steiner E, Puhl A, Pilch H, et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008;68:5405-13.
31. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol 2007;7:118-30.
32. Cosgun KN, Rahmig S, Mende N, Reinke S, Hauber I, Schafer C, et al. Kit regulates HSC engraftment across the human-mouse species barrier. Cell Stem Cell 2014;15:227-38.
33. King M, Pearson T, Shultz LD, Leif J, Bottino R, Trucco M, et al. A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene. Clin Immunol 2008;126:303-14.